In 1966 Chaldakov graduated as an
MD from Varna Institute of Medicine (since 1991, named
Medical University of Varna),
Varna, Bulgaria.[1] In 1983 he obtained a
PhD in Vascular Biology, "Ultrastructural and cytopharmacological study of aging in vascular smooth muscle cells, with special reference to their secretory function".[2] Since 2007, Chaldakov has served as
Professor Emeritus at Medical University of Varna, Bulgaria.[citation needed]
For the past 30 years Chaldakov has been involved in interdisciplinary research in the fields of
vascular biology, and has had relationship with such
adipobiology, and
neurobiology and is one of the pioneers establishing the novel concept of the
secretory function/
phenotype of the vascular smooth muscle cells and further delineating their role in
atherogenesis. Chaldakov developed a complex tripartite model of atherogenesis which involve smooth muscle cells,
immune cells, and perivascular adipose tissue communicating through secreted factors (e.g.
neurotrophins,
adipokines,
cytokines).
In 1991, Chaldakov became founder and chief editor of Biomedical Reviews, An International Journal of Cell Biology of Disease. He has also been an organizer of Biomedical Forum, Annual Program of Continuing Medical Education held at Medical University of Varna, Bulgaria.
Innovations and substantial contributions to science
Concept of the
neurotrophinsNGF and
BDNF as metabotrophic factors (metabotrophins) in cardiometabolic biology/diseases.[9][10]
Conceptualize the protein secretory products of
adipose tissue cells as adipokines, also focusing on perivascular adipose tissue.[11][12][13]
Conceptualize studying adipose tissue-directed pharmacology as adipopharmacology.[14][15][16]
In 2006 introduced the term Homo obesus and is actively involved in popularizing the need of healthy
lifestyle and dietary restriction: millions of people suffer and die from starvation in ill-developed and poor countries while in
Western world and
Europe people get
overweight and die as a result of
strokes or
heart infarctions.[17][18]
^
Chaldakov GN, Nikolov SD (1975). "Ultrastructure of the arterial smooth muscle cell". In Stewart Wolf, Nicholas Theodore Werthessen (eds.). Smooth Muscle of the Artery.
New York City: Plenum Press. pp. 14–20.
ISBN978-0-306-39057-9.
OCLC1288413.
^
Chaldakov GN, Nikolov SD, Vankov VN (1977). "Fine morphological aspects of the secretory process of arterial smooth muscle cells. II. Role of microtubules". Acta Morphologica Academiae Scientiarum Hungaricae. 25 (2–3): 167–174.
PMID615419.
^
Chaldakov GN, Vankov VN (1986). "Morphological aspects of secretion in the arterial smooth muscle cell, with special reference to the Golgi complex and microtubular cytoskeleton". Atherosclerosis. 61 (3): 175–192.
doi:
10.1016/0021-9150(86)90137-1.
PMID3533092.
^
Chaldakov GN (1982). "Antitubulins - a new therapeutic approach for atherosclerosis?". Atherosclerosis. 44 (3): 385–390.
doi:
10.1016/0021-9150(82)90013-2.
^
Chaldakov GN, Vankov VN (1986). "Antifibrotic approach in the therapy of arterial occlusive diseases: new considerations". In Gustav Trübestein (ed.). Konservative Therapie arterieller Durchblutungsstörungen [Conservative Therapy of Arterial Occlusive Disease].
Stuttgart:
Thieme Medical Publishers. pp. 224–226.
ISBN978-3-13-688101-9.
OCLC246829648.
^
Manni L, Nikolova V, Vyagova D, Chaldakov GN, Aloe L (2005). "Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes". International Journal of Cardiology. 102 (1): 169–171.
doi:
10.1016/j.ijcard.2004.10.041.
PMID15939120.
^
Chaldakov GN; Fiore M; Ghenev PI; Stankulov IS Aloe L (2000). "Atherosclerotic lesions: possible interactive involvement of intima, adventitia and associated adipose tissue". The International Medical Journal. 7: 43–49.
^
Chaldakov GN, Stankulov IS, Aloe L (2001). "Subepicardial adipose tissue in human coronary atherosclerosis: another neglected phenomenon". Atherosclerosis. 154 (1): 237–238.
doi:
10.1016/S0021-9150(00)00676-6.
PMID11190652.
^
Chaldakov GN, Stankulov IS, Fiore M, Ghenev PI, Aloe L (2001). "Nerve growth factor levels and mast cell distribution in human coronary atherosclerosis". Atherosclerosis. 159 (1): 57–66.
doi:
10.1016/S0021-9150(01)00488-9.
PMID11689207.
^
Chaldakov GN, Stankulov IS, Hristova MG, Ghenev PI (2003). "Adipobiology of disease: adipokines and adipokine-targeted pharmacology". Current Pharmaceutical Design. 9 (12): 1023–1031.
doi:
10.2174/1381612033455152.
PMID12678860.
^
Chaldakov GN, Fiore M, Hristova M, Aloe L (2000). "Cell biology and pharmacology of adipose tissue secretion". FABAD Journal of Pharmaceutical Sciences. 25: 181–191.
^
Chaldakov GN, Fiore M, Tonchev AB, Aloe L (2006). "Adipopharmacology, a novel drug discovery approach: a metabotrophic perspective". Letters in Drug Design & Discovery. 3 (7): 503–505.
doi:
10.2174/157018006778194835.
^
Chaldakov GN, Fiore M, Tonchev AB, Dimitrov D, Pancheva R, Rancic G, Aloe L (2007). "Homo obesus: a metabotrophin-deficient species. Pharmacology and nutrition insight". Current Pharmaceutical Design. 13 (21): 2176–2179.
doi:
10.2174/138161207781039616.
PMID17627549.